Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.

BACKGROUND Children who have been hospitalized with severe anemia in areas of Africa in which malaria is endemic have a high risk of readmission and death within 6 months after discharge. No prevention strategy specifically addresses this period. METHODS We conducted a multicenter, two-group, randomized, placebo-controlled trial in nine hospitals in Kenya and Uganda to determine whether 3 months of malaria chemoprevention could reduce morbidity and mortality after hospital discharge in children younger than 5 years of age who had been admitted with severe anemia. All children received standard in-hospital care for severe anemia and a 3-day course of artemether-lumefantrine at discharge. Two weeks after discharge, children were randomly assigned to receive dihydroartemisinin-piperaquine (chemoprevention group) or placebo, administered as 3-day courses at 2, 6, and 10 weeks after discharge. Children were followed for 26 weeks after discharge. The primary outcome was one or more hospital readmissions for any reason or death from the time of randomization to 6 months after discharge. Conditional risk-set modeling for recurrent events was used to calculate hazard ratios with the use of the Prentice-Williams-Peterson total-time approach. RESULTS From May 2016 through May 2018, a total of 1049 children underwent randomization; 524 were assigned to the chemoprevention group and 525 to the placebo group. From week 3 through week 26, a total of 184 events of readmission or death occurred in the chemoprevention group and 316 occurred in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], 0.54 to 0.78; P<0.001). The lower incidence of readmission or death in the chemoprevention group than in the placebo group was restricted to the intervention period (week 3 through week 14) (hazard ratio, 0.30; 95% CI, 0.22 to 0.42) and was not sustained after that time (week 15 through week 26) (hazard ratio, 1.13; 95% CI, 0.87 to 1.47). No serious adverse events were attributed to dihydroartemisinin-piperaquine. CONCLUSIONS In areas with intense malaria transmission, 3 months of postdischarge malaria chemoprevention with monthly dihydroartemisinin-piperaquine in children who had recently received treatment for severe anemia prevented more deaths or readmissions for any reason after discharge than placebo. (Funded by the Research Council of Norway and the Centers for Disease Control and Prevention; ClinicalTrials.gov number, NCT02671175.).

[1]  J. Walson,et al.  Seeking interventions to reduce post-discharge mortality among children in sub-Saharan Africa. , 2019, The Lancet. Global health.

[2]  K. Maitland,et al.  Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trial , 2019, The Lancet. Global health.

[3]  K. Maitland,et al.  Immediate Transfusion in African Children with Uncomplicated Severe Anemia. , 2019, The New England journal of medicine.

[4]  K. Maitland,et al.  Transfusion Volume for Children with Severe Anemia in Africa. , 2019, The New England journal of medicine.

[5]  Steve M. Taylor,et al.  Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. , 2019, The Lancet. Infectious diseases.

[6]  D. Havlir,et al.  Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial , 2019, The Lancet.

[7]  B. Blomberg,et al.  Introducing post-discharge malaria chemoprevention (PMC) for management of severe anemia in Malawian children: a qualitative study of community health workers’ perceptions and motivation , 2018, BMC Health Services Research.

[8]  Duolao Wang,et al.  Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial , 2018, Trials.

[9]  B. Robberstad,et al.  Post-discharge malaria chemoprevention (PMC) in Malawi: caregivers` acceptance and preferences with regard to delivery methods , 2018, BMC Health Services Research.

[10]  L. Okell,et al.  Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa , 2017, Scientific Reports.

[11]  A. York Seasonal malaria chemoprevention in the Sahel. , 2017, The Lancet. Infectious diseases.

[12]  M. Karlsson,et al.  Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine , 2017, Antimicrobial Agents and Chemotherapy.

[13]  A. Stergachis,et al.  Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis , 2017, The Lancet. Infectious diseases.

[14]  P. Bangirana,et al.  High Postdischarge Morbidity in Ugandan Children With Severe Malarial Anemia or Cerebral Malaria , 2016, Journal of the Pediatric Infectious Diseases Society.

[15]  N. Kissoon,et al.  Postdischarge mortality in children with acute infectious diseases: derivation of postdischarge mortality prediction models , 2015, BMJ Open.

[16]  K. Maitland,et al.  Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness , 2015, BMC Medicine.

[17]  P. Rosenthal,et al.  Protective Efficacy and Safety of Three Antimalarial Regimens for the Prevention of Malaria in Young Ugandan Children: A Randomized Controlled Trial , 2014, PLoS medicine.

[18]  E. Purssell,et al.  Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? , 2014, Malaria research and treatment.

[19]  Seth R Flaxman,et al.  A systematic analysis of global anemia burden from 1990 to 2010. , 2014, Blood.

[20]  B. Faragher,et al.  Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial. , 2012, The Lancet. Infectious diseases.

[21]  K. Maitland,et al.  Changing trends in blood transfusion in children and neonates admitted in Kilifi District Hospital, Kenya , 2010, Malaria Journal.

[22]  D. Conway,et al.  A Randomised Trial to Compare the Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children , 2010, PloS one.

[23]  D. Conway,et al.  Prevention of the Recurrence of Anaemia in Gambian Children Following Discharge from Hospital , 2010, PloS one.

[24]  B. Cissé,et al.  Randomized Trial of Piperaquine with Sulfadoxine-Pyrimethamine or Dihydroartemisinin for Malaria Intermittent Preventive Treatment in Children , 2009, PloS one.

[25]  F. Binka,et al.  Seasonal Intermittent Preventive Treatment for the Prevention of Anaemia and Malaria in Ghanaian Children: A Randomized, Placebo Controlled Trial , 2008, PloS one.

[26]  J. Vulule,et al.  Causes of deaths using verbal autopsy among adolescents and adults in rural western Kenya , 2008, Tropical medicine & international health : TM & IH.

[27]  M. Molyneux,et al.  Long Term Outcome of Severe Anaemia in Malawian Children , 2008, PloS one.

[28]  D. Kwiatkowski,et al.  Research Article ( New England Journal of Medicine ) Severe anemia in Malawian children , 2016 .

[29]  F. T. Ter Kuile,et al.  Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. , 2007, JAMA.

[30]  B. Cissé,et al.  Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial , 2006, The Lancet.

[31]  R. Steketee,et al.  Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery , 1997, AIDS.

[32]  K. Bojang,et al.  Management of severe malarial anaemia in Gambian children. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[33]  O. Rodrigues,et al.  Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria , 1997, British journal of haematology.

[34]  B. Metchock,et al.  Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. , 1996, The American journal of tropical medicine and hygiene.

[35]  A. V. Peterson,et al.  On the regression analysis of multivariate failure time data , 1981 .